In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET
In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET
复制标题
DOI：
10.2967/jnumed.113.121897
复制
发表时间：
2014-01-01
影响因子：
9.3
通讯作者：
Weng, Yi-Hsin
中科院分区：
文献类型：
--
作者：
Lin, Shao-Cheng;Lin, Kun-Ju;Weng, Yi-Hsin
具有F-18-9-氟丙基-（+）-二氢四苯并嗪（F-18-DTBZ）的PET（一种靶向囊泡单胺转运体2型（VMAT 2）的新型放射性示踪剂）已被证明是测量多巴胺能完整性的有用的成像标记物。研究方法：本研究的目的是评价18F-DTBZ PET在体内检测早期帕金森病（PD）单胺能变性的能力。17例年龄匹配的健康受试者和30例疾病早期（疾病持续时间）的PD患者
PET with F-18-9-fluoropropyl-(+)-dihydrotetrabenzazine (F-18-DTBZ), a novel radiotracer targeting vesicular monoamine transporter type 2 (VMAT2), has been proven as a useful imaging marker to measure dopaminergic integrity. Methods: The aim of this study was to evaluate the capability of 18F-DTBZ PET in detecting the monoaminergic degeneration in early Parkinson disease (PD) in vivo. Seventeen age-matched healthy subjects and 30 PD patients at early stage of disease (duration of disease